{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:57:42Z","timestamp":1783011462132,"version":"3.54.6"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1023\/a:1023952106955","type":"journal-article","created":{"date-parts":[[2003,6,9]],"date-time":"2003-06-09T16:05:44Z","timestamp":1055174744000},"page":"201-205","source":"Crossref","is-referenced-by-count":23,"title":["Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer"],"prefix":"10.1007","volume":"63","author":[{"given":"C.C.P.","family":"Verstappen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hoekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Heimans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"5125182_CR1","unstructured":"Neijt JP, Allen DG, Colombo N: Carcinoma of the ovary. In: Peckham M, Pinedo HB, Veronesi U (eds), Oxford Text Book of Oncology 1995, pp 1293-1307"},{"key":"5125182_CR2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1023\/A:1008230909599","volume":"8","author":"C Trope","year":"1997","unstructured":"Trope C, Kaern J, Kristensen G, Rosenberg P, Sorbe B: Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer. Ann Oncol 8: 803-806, 1997","journal-title":"Ann Oncol"},{"key":"5125182_CR3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/gyno.1996.4514","volume":"64","author":"K Mayerhofer","year":"1997","unstructured":"Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P: Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Gynecol Oncol 64: 109-113, 1997","journal-title":"Gynecol Oncol"},{"key":"5125182_CR4","first-page":"4417","volume":"50","author":"LW Hertel","year":"1990","unstructured":"Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the anti-tumor activity of gemcitabine (difluoro-2-deoxycytidine). Cancer Res 50: 4417-4420, 1990","journal-title":"Cancer Res"},{"key":"5125182_CR5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/oxfordjournals.annonc.a058910","volume":"5","author":"G Catimel","year":"1994","unstructured":"Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J et al.: A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 543-547, 1994","journal-title":"Ann Oncol"},{"key":"5125182_CR6","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","volume":"86","author":"B Lund","year":"1994","unstructured":"Lund B, Hansen OP, Neijt JP, Theilade K, Hansen M: Phase II study of gemcitabine (2',2'-difluorodeoxycytydine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533, 1994","journal-title":"J Natl Cancer Inst"},{"key":"5125182_CR7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","volume":"63","author":"JD Shapiro","year":"1996","unstructured":"Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89-93, 1996","journal-title":"Gynecol Oncol"},{"key":"5125182_CR8","first-page":"521","volume":"2","author":"AM Bergman","year":"1996","unstructured":"Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ: Synergistic interaction between gemcitabine and cisplatin in vitro. Clin Cancer Res 2: 521-530, 1996","journal-title":"Clin Cancer Res"},{"issue":"Suppl.10","key":"5125182_CR9","first-page":"16","volume":"23","author":"GJ Peters","year":"1996","unstructured":"Peters GJ, Ruiz van Haperen VWT, Bergman AM, Veerman G, Smitskamp-Wilms E, van Moorsel CJ, Kuiper CM, Braakhuis BJ: Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 23 (Suppl. 10): 16-24, 1996","journal-title":"Semin Oncol"},{"key":"5125182_CR10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0959-8049(99)00004-0","volume":"35","author":"CJ van Moorsel","year":"1999","unstructured":"van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ: Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 35: 808-814, 1999","journal-title":"Eur J Cancer"},{"key":"5125182_CR11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.1997.15.1.297","volume":"15","author":"L Crino","year":"1997","unstructured":"Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronato P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C, Tonato M: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer (NSCLC). A phase II study. J Clin Oncol 15: 297-303, 1997","journal-title":"J Clin Oncol"},{"key":"5125182_CR12","first-page":"65a","volume":"16","author":"I Krakowski","year":"1997","unstructured":"Krakowski I, Delpomme D, Beaduin M et al.: Gemcitabine (GEM) in combination with cisplatin (CP) in stage III or IV ovarian cancer: preliminary phase II results. Proc ASCO 16: 65a (Abstract 1300), 1997","journal-title":"Proc ASCO"},{"key":"5125182_CR13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00001813-200209000-00009","volume":"13","author":"M Nogue","year":"2002","unstructured":"Nogue M, Cirera L, Arcusa M, Batiste-Alentorn E, Balil A, Font A, Perez-Gracia JL, carrasco EM, Tusquets I: Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anticancer Drugs 13: 839-845, 2002","journal-title":"Anticancer Drugs"},{"key":"5125182_CR14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/gyno.1996.0210","volume":"62","author":"E Connelly","year":"1996","unstructured":"Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J: Paclitaxel delivered as a 3-h infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 62: 166-168, 1996","journal-title":"Gynecol Oncol"},{"key":"5125182_CR15","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1200\/JCO.1993.11.10.2010","volume":"11","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Comblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010-dy2020, 1993","journal-title":"J Clin Oncol"},{"issue":"Suppl.10","key":"5125182_CR16","first-page":"32","volume":"23","author":"MR Green","year":"1996","unstructured":"Green MR: Gemcitabine safety overview. Semin Oncol 23(Suppl. 10): 32-35, 1996","journal-title":"Semin Oncol"},{"key":"5125182_CR17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0140-6736(05)78426-9","volume":"351","author":"AJ Dormann","year":"1998","unstructured":"Dormann AJ, Gr\u00fcnwald T, Wigginghaus B, Huchzermeyer H: Gemcitabine-associated autonomic neuropathy. The Lancet 351: 644, 1998","journal-title":"The Lancet"},{"key":"5125182_CR18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/oxfordjournals.annonc.a059220","volume":"6","author":"TJ Postma","year":"1995","unstructured":"Postma TJ, Vermorken JB, Liefting AJM, Pinedo HM, Heimans JJ: Paclitaxel-induced neuropathy. Ann Oncol 6: 489-494, 1995","journal-title":"Ann Oncol"},{"key":"5125182_CR19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1006343818656","volume":"45","author":"TJ Postma","year":"1999","unstructured":"Postma TJ, Hoekman K, van Riel JMGH, Heimans JJ, Vermorken JB: Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. J Neuro-Oncol 45: 241\u2013246, 1999","journal-title":"J Neuro-Oncol"},{"key":"5125182_CR20","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1200\/JCO.1999.17.8.2316","volume":"17","author":"G Frasci","year":"1999","unstructured":"Frasci G, Panza N, Comella P, Nicolella GP, Natale M, Manzione L, Bilancia D, Cioffi R, Maiorino L, De Cataldis G, Belli M, Micillo E, Mascia V, Massidda B, Lorusso V, De Lena M, Carpagnano F, Contu A, Pusceddu G, Comella G: Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. J Clin Oncol 17: 2316-2325, 1999","journal-title":"J Clin Oncol"},{"key":"5125182_CR21","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/1097-0142(19900915)66:6<1117::AID-CNCR2820660607>3.0.CO;2-O","volume":"66","author":"T Siegal","year":"1990","unstructured":"Siegal T, Haim N: Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndrome, and muscle cramps. Cancer 66: 1117-1123, 1990","journal-title":"Cancer"},{"key":"5125182_CR22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.1992.10.5.795","volume":"10","author":"RW Gregg","year":"1992","unstructured":"Gregg RW, Molepo JM, Monpetit VJA, Mikael NZ, Redmind D, Gadia M, Stewart DJ: Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphological evidence of toxicity. J Clin Oncol 10: 795-803, 1992","journal-title":"J Clin Oncol"},{"key":"5125182_CR23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/1097-0142(19950301)75:5<1141::AID-CNCR2820750514>3.0.CO;2-U","volume":"75","author":"G Cavaletti","year":"1995","unstructured":"Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, Tredici G: Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75: 1141-1150, 1995","journal-title":"Cancer"},{"key":"5125182_CR24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1212\/WNL.51.3.868","volume":"51","author":"C Iniguez","year":"1998","unstructured":"Iniguez C, Larrode P, Mayordomo JI, Gonzales P, Adelantado S, Yubero A, Tres A, Morales F: Reversible peripheral neuropathy induced by single administration of high-dose paclitaxel. Neurology 51: 868-700, 1998","journal-title":"Neurology"},{"key":"5125182_CR25","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris III","year":"1997","unstructured":"Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1023952106955.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1023952106955\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1023952106955.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T09:13:10Z","timestamp":1749633190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1023952106955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["5125182"],"URL":"https:\/\/doi.org\/10.1023\/a:1023952106955","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}